Evidence map›Paper›PMID 35431503›Full record

ReviewWorld journal of gastroenterology2022

Advanced imaging and artificial intelligence for Barrett's esophagus: What we should and soon will do.

Marco Spadaccini, Edoardo Vespa, Viveksandeep Thoguluva Chandrasekar, Madhav Desai, Harsh K Patel, Roberta Maselli, Alessandro Fugazza, Silvia Carrara, Andrea Anderloni, Gianluca Franchellucci and 5 more

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Marco SpadacciniDepartment of Endoscopy, Humanitas Research Hospital, IRCCS, Rozzano 20089, Italy.
Edoardo VespaDepartment of Endoscopy, Humanitas Research Hospital, IRCCS, Rozzano 20089, Italy.
Viveksandeep Thoguluva ChandrasekarDepartment of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ 85054, United States.
Madhav DesaiDepartment of Gastroenterology and Hepatology, Kansas City VA Medical Center, Kansas City, MO 66045, United States.
Harsh K PatelDepartment of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA 70124, United States.
Roberta MaselliDepartment of Endoscopy, Humanitas Research Hospital, IRCCS, Rozzano 20089, Italy.
Alessandro FugazzaDepartment of Endoscopy, Humanitas Research Hospital, IRCCS, Rozzano 20089, Italy.
Silvia CarraraDepartment of Endoscopy, Humanitas Research Hospital, IRCCS, Rozzano 20089, Italy.
Andrea AnderloniDepartment of Endoscopy, Humanitas Research Hospital, IRCCS, Rozzano 20089, Italy.
Gianluca FranchellucciDepartment of Endoscopy, Humanitas Research Hospital, IRCCS, Rozzano 20089, Italy.
Alessandro De MarcoDepartment of Endoscopy, Humanitas Research Hospital, IRCCS, Rozzano 20089, Italy.
Cesare HassanEndoscopy Unit, Nuovo Regina Margherita Hospital, Roma 00153, Italy.
Pradeep BhandariDepartment of Gastroenterology, Portsmouth Hospitals University NHS Trust, Portsmouth PO6 3LY, United Kingdom.
Prateek SharmaDepartment of Gastroenterology and Hepatology, Kansas City VA Medical Center, Kansas City, MO 66045, United States.
Alessandro RepiciDepartment of Endoscopy, Humanitas Research Hospital, IRCCS, Rozzano 20089, Italy.
IRCCS Humanitas Research Hospital · ITKansas City VA Medical Center · USMayo Clinic in Arizona · USOchsner Medical Center · USOspedale Regina Margherita · ITPortsmouth Hospitals NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Barrett's esophagus (BE) is a well-established risk factor for esophageal adenocarcinoma. It is recommended that patients have regular endoscopic surveillance, with the ultimate goal of detecting early-stage neoplastic lesions before they can progress to invasive carcinoma. Detection of both dysplasia or early adenocarcinoma permits curative endoscopic treatments, and with this aim, thorough endoscopic assessment is crucial and improves outcomes. The burden of missed neoplasia in BE is still far from being negligible, likely due to inappropriate endoscopic surveillance. Over the last two decades, advanced imaging techniques, moving from traditional dye-spray chromoendoscopy to more practical virtual chromoendoscopy technologies, have been introduced with the aim to enhance neoplasia detection in BE. As witnessed in other fields, artificial intelligence (AI) has revolutionized the field of diagnostic endoscopy and is set to cover a pivotal role in BE as well. The aim of this commentary is to comprehensively summarize present evidence, recent research advances, and future perspectives regarding advanced imaging technology and AI in BE; the combination of computer-aided diagnosis to a widespread adoption of advanced imaging technologies is eagerly awaited. It will also provide a useful step-by-step approach for performing high-quality endoscopy in BE, in order to increase the diagnostic yield of endoscopy in clinical practice.

Indexed as

AdenocarcinomaBarrett EsophagusEsophageal NeoplasmsArtificial IntelligenceEndoscopyEsophagoscopyHumansAdvanced imagingArtificial intelligenceBarrett’s esophagusEndoscopyNeoplasiaSurveillance

Identifiers

PMID35431503
PMCPMC8985480
OpenAlexW4221119740

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.